MyelinWatch EL
← Pipeline
Human clinical dataCompletedNull

Phase 2 • completed

ReWRAP

Bazedoxifene acetate

Compound / intervention
Bazedoxifene acetate
Mechanism
Bazedoxifene; selective oestrogen-receptor modulation
Development stage
Phase 2 • completed
Status
Primary and secondary remyelination endpoints not met
Evidence level
Human Phase 2 • null remyelination efficacy endpoints
Next substantive checkpoint

Generally well tolerated, but without a statistically significant efficacy signal

ClinicalTrials.govOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

Human clinical dataCompletedNull

Phase 2

ReWRAP: bazedoxifene missed remyelination endpoints in Phase 2

In ReWRAP, bazedoxifene was generally well tolerated but did not produce a statistically significant improvement in the primary MRI myelin-water-fraction endpoint or secondary efficacy endpoints.

What this means clinically

Another agent with strong preclinical evidence did not translate its remyelination signal into a positive human Phase 2 result.

Source quality: High • completed trial registry plus ACTRIMS presentation

ClinicalTrials.govClinicalTrials.gov / ACTRIMS 2026 ↗